Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 12/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.37 |
| ▸ | TNF | P01375 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 4/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31404984 | 0.85 | IL1B (0.39) | IL1BNLRP3TNFMAPTRAB9A | |
| SCHEMBL31404971 | 0.82 | IL1B (0.58) | IL1BNLRP3TNF | |
| SCHEMBL31405017 | 0.75 | IL1B (0.41) | IL1BNLRP3TNF | |
| SCHEMBL31200596 | 0.69 | IL1B (0.45) | IL1BNLRP3TNFRAB9A | |
| SCHEMBL22670876 | 0.69 | IL1B (0.45) | IL1BNLRP3TNFRAB9A | |
| SCHEMBL2172009 | 0.69 | ALDH1A1 (0.46) | KDM4EMAPTTDP1 | |
| SCHEMBL31404979 | 0.68 | IL1B (0.58) | IL1BNLRP3TNF | |
| SCHEMBL31233661 | 0.68 | NLRP3 (0.39) | IL1BNLRP3MAPT | |
| SCHEMBL11209199 | 0.67 | CYP3A4 (0.64) | KDM4EMAPTTDP1 | |
| SCHEMBL698657 | 0.66 | KDM4E (0.52) | KDM4EMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2025-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | IL1B, NLRP3, NOD1 | IL1B 1/4885NLRP3 2/4885TNF 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.